arrow
P

Peter C. Lucas

Mayo Clinic
H指数:55
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression in mice

MALT1蛋白酶抑制通过逆转肿瘤相关巨噬细胞依赖的免疫抑制抑制胶质母细胞瘤进展(在小鼠中)

2026-08-100
OA
Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women
2026-07-270
OA
Non-invasive profiling of the tumour microenvironment with spatial ecotypes

无创性空间生态型表征肿瘤微环境

Nature
IF48.5
2026-05-060
OAAI
EWSR1-Rearranged Renal Neoplasia: Clinicopathologic and Molecular Characterization of 39 Cases from a Single Institution

EWSR1重排性肾肿瘤:单机构39例的临床病理及分子特征

2026-04-300
PRE
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy

p95HER2,HER2癌蛋白的一种截断形式,在HER2+乳腺癌中驱动一种免疫抑制程序,限制了T-DXd(trastuzumab deruxtecan)的疗效。

2025-06-270
PRE
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction The NRG-BR005 Nonrandomized Clinical Trial

乳腺癌瘤床活检用于预测病理完全缓解:NRG-BR005非随机临床试验

2025-05-071
PRE
Renal Neoplasia in Birt-Hogg-Dubé Syndrome: Integrated Histopathologic, Bulk, and Single-cell Transcriptomic Analysis

Birt-Hogg-Dubé综合征中的肾肿瘤:整合组织病理学、批量分析和单细胞转录组分析

2025-04-180
PRE
ENGINEERING MRNA THERAPIES FOR BRAIN TUMORS
2024-11-110
PRE
Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations
2024-07-231
PRE
MALT1 IN H3K27-ALTERED DIFFUSE MIDLINE GLIOMA
2024-06-180
OAAI
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer (vol 26, 69, 2024)
2024-05-240
OAAI
Loco-Regional Irradiation in Patients with Biopsyproven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
2024-05-022
PRE
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

NSABP FB-10: 一项Ib/II期试验评估ado-曲妥珠单抗emtansine (T-DM1) 联合neratinib治疗转移性HER2-positive乳腺癌患者

2024-04-221
OAAI
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

来自NRG肿瘤学/NSABP B-42试验的乳腺癌指数和激素受体阳性乳腺癌中延长芳香化酶抑制剂治疗益处的预测

2024-02-204
OAAI